HG linked to higher risks for preeclampsia, gestational hypertension, preterm birth, SGA, placental abruption, anemia ...

Topline data from the phase 3 E-BEOND and C-BEOND trials show a significant reduction in monthly migraine days at 24 weeks, demonstrating efficacy across the full migraine spectrum.

FDA Drug Approvals and Regulatory Updates Drug Pharmacologic class Indication More information Cardiovascular Disease Tryngolza (olezarsen) Apolipoprotein ...

Rates of prostate cancer screening shared decision-making (SDM) are very low in family medicine practices, according to a study published in the June issue of the Southern Medical Journal. Nicholas ...

Three in 10 young adults do not have a primary care doctor, according to the results of a survey released June 29 by The Ohio State University Wexner Medical Ce ...

Label expansion establishes the therapy as the first VWF concentrate indicated for routine prophylaxis across all age groups ...

The phase 3 CARDIO-TTRansform trial evaluated subcutaneous eplontersen vs placebo in 1432 adults with ATTR-CM.

In the INTEGUMENT-INFANT trial, 34.4% of patients achieved vIGA-AD success and 58.3% reached EASI-75 at week 4.

Backed by phase 3 RINGSIDE data showing an 84% reduction in the risk of disease progression or death, the investigational agent moves ahead in the regulatory pipeline.

A Prescription Drug User Fee Act target date of November 1, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug ...

Researchers found that 140 individuals (32.1%) reported lifetime GLP-1 RA use and 96 (22.0%) reported current use. HealthDay ...

A parasite that causes severe, watery diarrhea is spreading across the US, and health officials in Michigan are racing to ...